| pubmed-article:2495717 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0042071 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0019080 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0002726 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0085973 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0007320 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0282441 | lld:lifeskim |
| pubmed-article:2495717 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:2495717 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2495717 | pubmed:dateCreated | 1989-5-19 | lld:pubmed |
| pubmed-article:2495717 | pubmed:abstractText | Hyperfibrinolytic states are reported to be a cause of bleeding in patients with amyloidosis. We reviewed the literature on excessive fibrinolysis in association with amyloidosis and report our findings from a patient with idiopathic amyloidosis who developed a bleeding diathesis. Coagulation laboratory studies indicated elevated plasminogen activator levels associated with a reduction of plasminogen and alpha 2-plasmin inhibitor (alpha 2-PI) levels. The level of tissue-type plasminogen activator (t-PA) inhibitor and t-PA antigen were normal. However, the patient did have a five- to sevenfold increase in amidolytic activity for the urokinase substrate pyro-Glu-Gly-Arg-pNA (S-2444). This case therefore represents a novel example of a hyperfibrinolytic state associated with amyloidosis caused by elevated urokinase-type plasminogen activator (u-PA). Epsilon-amino caproic acid (EACA) therapy resulted in an increase in alpha 2-PI and plasminogen levels and effectively reduced the blood loss. Hyperfibrinolytic states in amyloidosis have now been reported to be due to elevated t-PA and u-PA and depleted t-PA inhibitor. | lld:pubmed |
| pubmed-article:2495717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2495717 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2495717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2495717 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2495717 | pubmed:month | May | lld:pubmed |
| pubmed-article:2495717 | pubmed:issn | 0361-8609 | lld:pubmed |
| pubmed-article:2495717 | pubmed:author | pubmed-author:PizzoS VSV | lld:pubmed |
| pubmed-article:2495717 | pubmed:author | pubmed-author:GreenbergC... | lld:pubmed |
| pubmed-article:2495717 | pubmed:author | pubmed-author:SaneD CDC | lld:pubmed |
| pubmed-article:2495717 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2495717 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:2495717 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2495717 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2495717 | pubmed:pagination | 53-7 | lld:pubmed |
| pubmed-article:2495717 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:meshHeading | pubmed-meshheading:2495717-... | lld:pubmed |
| pubmed-article:2495717 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2495717 | pubmed:articleTitle | Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. | lld:pubmed |
| pubmed-article:2495717 | pubmed:affiliation | Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710. | lld:pubmed |
| pubmed-article:2495717 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2495717 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2495717 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:2495717 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:2495717 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
